SERVICES

Tag Archives | FDA Orphan Drug Designation

Press Release: Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Kabuki Syndrome

CARY, N.C., Feb. 12, 2021 (SEND2PRESS NEWSWIRE) — Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation for the Company’s lead drug RSC-57, for the treatment […]

Continue Reading
Epeius

Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma

SAN MARINO, Calif., July 8 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the […]

Continue Reading

Part of the Neotrope® News Network, USA. Neotrope.net